Unreported / Non-Citable
Background
Plaintiffs Butterfli Rain and Crystal Perez filed a putative class action alleging that Peach and Lily's Peach Slices "Snail Rescue All-In-One 'Oil Free' Moisturizer" and "Acne 'Oil-Free' Moisturizer" were misleadingly labeled because they contain ingredients plaintiffs characterize as oils or oil-derived substances, including cetyl ethylhexanoate, cetearyl alcohol, sorbitan olivate, cetearyl olivate, caprylic/capric triglyceride, and glyceryl stearate.
Plaintiffs asserted claims under California's Unfair Competition Law, False Advertising Law, Consumers Legal Remedies Act, and for breach of express warranty, unjust enrichment, and intentional and negligent misrepresentation. Peach and Lily removed the case under the Class Action Fairness Act and moved to dismiss on FDCA preemption, failure-to-state-a-claim, and standing grounds, alternatively seeking a stay under the primary jurisdiction doctrine.
The Court held a hearing on November 19, 2026, and issued this order on November 20, 2026.
The Court’s Holding
The Court rejected FDCA preemption, reasoning that plaintiffs challenge the "oil-free" advertising statement rather than the completeness of the ingredient list, and that under Astiana v. Hain Celestial Group, removing misleading cosmetic advertising statements does not conflict with federal labeling rules.
The Court declined to invoke primary jurisdiction or stay the case for FDA resolution, finding that deciding whether a term is false or misleading is within the courts' province and that a stay would needlessly delay the case given the FDA's lack of demonstrated interest in defining "oil-free" cosmetics.
The Court denied dismissal of the claims about the two purchased products, finding factual disputes over whether the ingredients are oils and whether reasonable consumers would expect "Oil-Free" to exclude oil-derived ingredients. It dismissed claims about unspecified unpurchased products under Rule 9(b) without prejudice and with leave to amend.
Key Takeaways
- A cosmetics false-advertising claim challenging a front-label "oil-free" representation is not preempted merely because the manufacturer complied with FDCA ingredient-listing requirements.
- Whether "oil-free" misleadingly implies exclusion of oil-derived ingredients presents a factual question about reasonable consumer expectations that generally cannot be resolved on a Rule 12(b)(6) motion.
- Courts may decline primary jurisdiction where no party has sought FDA action and the agency has shown no interest in defining the disputed term, particularly where a stay would needlessly delay resolution.
- Rule 9(b) requires plaintiffs challenging unpurchased products to identify the specific products and alleged misrepresentations; vague references to an entire product line are insufficient.
- Dismissals under Rule 9(b) are ordinarily without prejudice, and leave to amend should be granted where the defect may be curable.
Why It Matters
This order illustrates the pleading-stage viability of "oil-free" cosmetics labeling claims in the Northern District of California and reinforces Astiana's limit on FDCA preemption for challenges to advertising statements that contradict accurate ingredient lists.
The decision also shows that primary jurisdiction is discretionary and unlikely to support a stay where FDA action is speculative and the agency has not engaged with the challenged terminology.